Davis Polk & Wardwell acted for Japanese drugmaker Daiichi Sankyo Co. on the sale of its 9 percent stake in Mumbai-based Sun Pharmaceutical Industries Ltd., which reportedly raised $3.2 billion.
Daiichi had received the stake when it sold Indian generic drugmaker Ranbaxy Laboratories Ltd. to Sun Pharma earlier this month for $3.2 billion. Davis Polk advised the company on that transaction as well, with Shearman & Sterling representing Sun Pharma.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
